SG Americas Securities
KRYS icon

SG Americas Securities’s Krystal Biotech KRYS Stock Holding History

SG Americas Securities’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6M Buy
16,147
+10,248
+174% +$3.06M ﹤0.01% 1024
2026
Q1 		$1.52M Sell
5,899
-13,010
-69% -$3.46M ﹤0.01% 1522
2025
Q4 		$4.66M Buy
18,909
+15,591
+470% +$3.28M 0.01% 1124
2025
Q3 		$586K Sell
3,318
-9,289
-74% -$1.39M ﹤0.01% 1983
2025
Q2 		$1.73M Buy
12,607
+11,295
+861% +$1.66M 0.01% 845
2025
Q1 		$237K Buy
+1,312
New +$221K ﹤0.01% 2414
2024
Q4 		– Sell
-2,527
Closed -$460K – 3378
2024
Q3 		$460K Buy
2,527
+1,765
+232% +$340K ﹤0.01% 1758
2024
Q2 		$140K Sell
762
-6,245
-89% -$1.05M ﹤0.01% 2358
2024
Q1 		$1.25M Sell
7,007
-11,858
-63% -$1.65M 0.01% 1056
2023
Q4 		$2.34M Sell
18,865
-2,074
-10% -$230K 0.02% 616
2023
Q3 		$2.43M Buy
+20,939
New +$2.55M 0.03% 620
2023
Q2 		– Sell
-5,714
Closed -$457K – 2748
2023
Q1 		$457K Sell
5,714
-33,060
-85% -$2.6M 0.01% 1784
2022
Q4 		$3.07M Buy
38,774
+36,434
+1,557% +$2.7M 0.04% 402
2022
Q3 		$163K Sell
2,340
-20,130
-90% -$1.45M ﹤0.01% 2487
2022
Q2 		$1.48M Sell
22,470
-16,631
-43% -$1.03M 0.02% 954
2022
Q1 		$2.6M Sell
39,101
-13,369
-25% -$834K 0.02% 728
2021
Q4 		$3.67M Buy
52,470
+288
+0.6% +$16.8K 0.02% 652
2021
Q3 		$2.72M Buy
52,182
+16,141
+45% +$956K 0.01% 1006
2021
Q2 		$2.45M Sell
36,041
-1,709
-5% -$119K 0.01% 994
2021
Q1 		$2.91M Sell
37,750
-5,238
-12% -$381K 0.02% 801
2020
Q4 		$2.58M Sell
42,988
-13,891
-24% -$694K 0.01% 918
2020
Q3 		$2.45M Buy
56,879
+36,203
+175% +$1.57M 0.02% 629
2020
Q2 		$856K Buy
+20,676
New +$995K 0.01% 1566

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SG Americas Securities's KRYS Position: Q2 2026 in Review

SG Americas Securities increased its Krystal Biotech (KRYS) stake by 174% in Q2 2026, buying an estimated $3.06M and bringing the position to 16,147 shares worth $6M. The position accounts for ﹤0.01% of the portfolio, ranked #1024.

SG Americas Securities first reported a position in KRYS in Q2 2020 and has held it in 23 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • SG Americas Securities held 16,147 shares of Krystal Biotech worth $6M as of Q2 2026.
  • SG Americas Securities bought 10,248 Krystal Biotech shares in Q2 2026, an estimated $3.06M.
  • Krystal Biotech made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1024 holding.
  • SG Americas Securities first reported a position in Krystal Biotech in Q2 2020 and has held it in 23 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.